Propanc Biopharma, Inc. Quarterly Debt-to-equity in % from Q1 2020 to Q2 2024

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Propanc Biopharma, Inc. quarterly Debt-to-equity history and growth rate from Q1 2020 to Q2 2024.
Propanc Biopharma, Inc. Debt-to-equity for the quarter ending June 30, 2024 was -104 %, a 0.32% decline year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q2 2024	-104	-0.33	-0.32%	Jun 30, 2024
Q1 2024	-104	-0.22	-0.21%	Mar 31, 2024
Q4 2023	-105	-1.08	-1.04%	Dec 31, 2023
Q3 2023	-104	-0.21	-0.2%	Sep 30, 2023
Q2 2023	-103	+0.32	+0.31%	Jun 30, 2023
Q1 2023	-104	-0.52	-0.5%	Mar 31, 2023
Q4 2022	-104	-2	-1.96%	Dec 31, 2022
Q3 2022	-104	-2.7	-2.67%	Sep 30, 2022
Q2 2022	-104	-2.54	-2.51%	Jun 30, 2022
Q1 2022	-103	-1.34	-1.32%	Mar 31, 2022
Q4 2021	-102	-0.06	-0.06%	Dec 31, 2021
Q3 2021	-101	+0.56	+0.55%	Sep 30, 2021
Q2 2021	-101	+1.04	+1.02%	Jun 30, 2021
Q1 2021	-102	+0.4	+0.39%	Mar 31, 2021
Q4 2020	-102			Dec 31, 2020
Q3 2020	-102			Sep 30, 2020
Q2 2020	-102			Jun 30, 2020
Q1 2020	-102			Mar 31, 2020

* An asterisk sign (*) next to the value indicates that the value is likely invalid.